Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint
You might notice saggy skin, dryness, wrinkles, and possibly some hair loss
This tension is also fueling debates about responsible prescribing and pharmaceutical advertising
N.ShuklaP
These drugs also are helpful for people with sleep apnea, which is associated with high blood pressure and increased cardiac risk
Retatrutide has shown common side effects similar to other GLP-1 receptor agonists, including: Nausea Vomiting Diarrohea Constipation Abdominal discomfort or bloating Some trial participants experienced a slight increase in resting heart rate, which has also been observed with other GLP-1 receptor agonists